Josh N. Vo

Josh N. Vo

Auto-generated profile, based on publicly available information

Josh N. Vo

University of Michigan 1 Ann Arbor, MI

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PHPaul Harms
Paul Harms
MVMonique E. Verhaegen
Monique E. Verhaegen
JVJosh N. Vo
Josh N. Vo
JTJean C. Tien
Jean C. Tien
DPDrew Pratt
Drew Pratt
ACArul M. Chinnaiyan
Arul M. Chinnaiyan

1 September 2026 in Cancer Discovery
Verified
Journal Article
Closed access
JVJosh N. Vo
Josh N. Vo
YWYi-Mi Wu
Yi-Mi Wu
RWRui Wang
Rui Wang
TPTiffany Pham
Tiffany Pham
XCXuhong Cao
Xuhong Cao
ACArul M. Chinnaiyan
Arul M. Chinnaiyan
Short-read sequencing cannot determine whether co-occurring variants within a cancer gene lie on the same allele (cis) or opposing alleles (trans), a distinction with direct therapeutic consequences: trans configurations confirm biallelic tumor suppressor inactivation, whereas cis configurations generate compound oncogenic alleles with enhanced activity. Among 768 patients with prostate, breast, or ovarian cancers, we used mutational signatures to nominate cryptic genomic instability cases lacking a causative biallelic event on short-read sequencing. Long-read nanopore sequencing resolved 32 of 46 cryptic cases (69.6%) through methylation detection, long insertion resolution, and structural variant characterization, confirming trans inactivation in every resolved tumor suppressor case. Analysis of 4,496 MiOncoSeq samples identified 17,519 multi-hit gene pairs, 78.7% of which exceeded the 500 bp short-read phasing limit, and long-read phasing revealed recurrent compound cis alleles in NOTCH1, PIK3CA, PDGFRB, and KIT. Haplotype phasing addresses an overlooked gap in cancer variant interpretation and warrants integration into precision oncology.